AcuCort Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jonas Jonmark

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	4.3yrs
CEO ownership	0.2%
Management average tenure	no data
Board average tenure	6.8yrs

Recent management updates

Recent updates

CEO

Jonas Jonmark (53 yo)

4.3yrs

Tenure

Mr. Jonas Jonmark is the Chief Executive Officer at AcuCort AB (publ) since August 9, 2020. He had been the President of Alteco Medical AB (publ) until July 1, 2015. He has an MBA degree from Lund Universi...

Board Members

Name	Position	Tenure	Compensation	Ownership
Monica Wallter	Independent Director	3.8yrs	no data	no data
Anna Eriksrud	Independent Director	7.8yrs	no data	0.014% SEK 14.7k
Ebba Cecilia Fahraeus	Independent Chairman of the Board	6.8yrs	no data	0.067% SEK 72.6k
Alexandra Johnsson	Independent Director	6.8yrs	no data	0.0088% SEK 9.5k
Goran Tornling	Independent Director	3.8yrs	no data	no data

6.8yrs

Average Tenure

66yo

Average Age

Experienced Board: ACUC's board of directors are considered experienced (6.8 years average tenure).

AcuCort Management

Management criteria checks 1/4

Key information

Recent management updates

AcuCort AB (publ), Annual General Meeting, Jun 04, 2024

Chief Executive Officer exercised options to buy kr161k worth of stock.

Insufficient new directors

AcuCort AB (publ), Annual General Meeting, May 04, 2023

No independent directors

AcuCort AB (publ) Appoints Jonas Jönmark as New CEO, Effective August 9, 2020

Recent updates

All Patients Completed AcuCort's Phase IV Study ZEQ001

New major risk - Market cap size

AcuCort AB (publ) to Report Q3, 2024 Results on Nov 22, 2024

Acucort AB (Publ) Announces Launch of Zeqmelit®? Initiated - Now Available At Pharmacies

AcuCort AB (publ) to Report First Half, 2024 Results on Aug 23, 2024

AcuCort AB (publ), Annual General Meeting, Jun 04, 2024

First quarter 2024 earnings released

AcuCort AB (publ) Provides Update on Phase IV Study ZEQ001

AcuCort AB (publ) to Report Q1, 2024 Results on Apr 26, 2024

Chief Executive Officer exercised options to buy kr161k worth of stock.

New minor risk - Share price stability

AcuCort AB (publ) Announces Update on FDA Application Ahead of Launch in the USA

Full year 2023 earnings released: kr0.44 loss per share (vs kr0.47 loss in FY 2022)

Insufficient new directors

AcuCort AB (publ) Announces First Patient Using Zeqmelit in Study Ahead of Market Launch

AcuCort AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024

New major risk - Shareholder dilution

Third quarter 2023 earnings released

AcuCort AB (publ) has completed a Composite Units Offering.

AcuCort AB (publ) to Report Q3, 2023 Results on Nov 30, 2023

AcuCort AB (publ) to Report Q3, 2023 Results on Nov 10, 2023

Second quarter 2023 earnings released

AcuCort AB (publ) to Report Q2, 2023 Results on Aug 31, 2023

AcuCort AB (publ) to Report Q2, 2023 Results on Aug 11, 2023

AcuCort Receives Ethics Approval for Study with Zeqmelit®

Fda Requests Additional Information Prior to Acucort's Registration Application in the United States

AcuCort AB (publ), Annual General Meeting, May 04, 2023

AcuCort AB (publ) to Report Fiscal Year 2022 Final Results on Feb 24, 2023

AcuCort Submitted the Price and Subsidy Application to TLV Regarding Zeqmelit®

Acucort Receives Market Approval from the Finnish Medicines Agency for the Drug Zeqmelit

Acucort AB (Publ) Receives Granted Patent in Canada for the Company's Drug Zeqmelit™

AcuCort AB (publ) to Report Q3, 2022 Results on Nov 11, 2022

AcuCort Reports Positive Results from the Company's Questionnaire Study About Allergy Treatments

AcuCort AB (publ) Receives Marketing Authorization for the Drug Zeqmelit by the Norwegian Medicines Agency

AcuCort AB (publ) Receives Marketing Authorization for the Drug Zeqmelit by the Danish Medicines Agency

Second quarter 2022 earnings released

AcuCort AB (publ) to Report Q2, 2022 Results on Aug 12, 2022

No independent directors

Full year 2021 earnings released: kr0.58 loss per share (vs kr0.40 loss in FY 2020)

AcuCort AB (publ) to Report Q1, 2022 Results on Apr 28, 2022

AcuCort AB (publ) to Report Q1, 2022 Results on Apr 28, 2022

AcuCort AB (publ) is Exempted from the Application Fee by the U.S. Food and Drug Administration

New 90-day low: kr4.61

New 90-day low: kr5.12

New 90-day low: kr5.16

AcuCort AB (publ) Announces That the China National Intellectual Property Administration Has Granted the Company's Patent Application for Its Drug ISICORT®

AcuCort AB (publ) to Report Q3, 2020 Results on Nov 13, 2020

New 90-day high - kr7.16

AcuCort AB (publ) to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr5.24

New 90-day high - kr4.43

AcuCort AB (publ) Appoints Jonas Jönmark as New CEO, Effective August 9, 2020

CEO

Tenure

Board Members

Average Tenure

Average Age